CheckMate 9ER: Progression-free Survival, Overall Survival, and Objective

Two subject matter experts discuss survival and response data from the CheckMate 9ER trial comparing combination nivolumab/cabozantinib to sunitinib in patients with advanced ccRCC.

EP: 1.Overview of ccRCC and Introduction to the CheckMate 9ER Trial

EP: 2.A Closer Look at Study Design and Patient Demographics from the CheckMate 9ER Trial

Now Viewing

EP: 3.CheckMate 9ER: Progression-free Survival, Overall Survival, and Objective

EP: 4.Adverse Events Following Use of Nivolumab Plus Cabozantinib in Patients With Advanced ccRCC

EP: 5.A Post-hoc Analysis of CheckMate 9ER Data and Study Conclusions

EP: 6.Clinical Insights Surrounding CheckMate 9ER Updates and Use of Nivolumab Plus Cabozantinib in ccRCC

EP: 7.Recap: Combination Therapy Shows Promise in Renal Cell Carcinoma

Recent Videos

Related Content

---

Recap: Combination Therapy Shows Promise in Renal Cell Carcinoma

ONCOLOGY Staff

June 27th 2023

Article

Experts present and discuss new findings from the CheckMate 9ER trial, evaluating nivolumab plus cabozantinib vs sunitinib in renal cell carcinoma.

Related Content

---

Recap: Combination Therapy Shows Promise in Renal Cell Carcinoma

ONCOLOGY Staff

June 27th 2023

Article

Experts present and discuss new findings from the CheckMate 9ER trial, evaluating nivolumab plus cabozantinib vs sunitinib in renal cell carcinoma.